novo nordisk glp-1 receptor agonist expands patient access to authentic, FDA-approved Wegovy® via collaborations with multiple telehealth organizations Novo Nordisk promotes new GLP-1
Description
Triple GIP/GLP-1/glucagon receptor co-agonists The success of dual receptor agonists for the treatment of type 2 diabetes and obesity in clinical trials, including the approval of one such drug by the FDA and EMA (currently only for type 2 diabetes), has prompted the search for new combinatorial approaches

The episode calls for a paradigm shift in breast cancer care, promoting integrative and functional medicine

Heres what obesity medicine physicians have to say

CagriSema showed 22.7% weight loss in REDEFINE-1 Phase 3 trials

Patients must also consider the financial implications, as off-label use may not be NHS-funded, potentially incurring substantial private costs

R.ThurstonM
